Navigation Links
New Study Shows Impressive Results with Abutment-Free Sophono System
Date:2/7/2013

Boulder, Colo. (PRWEB) February 07, 2013

Children with the abutment-free, implantable bone conduction hearing device from Sophono, Inc., experienced significant improvement in hearing – without skin complications – according to a new study.

Sophono, Inc., is a Colorado-based medical device manufacturer. The Sophono Alpha System™ is the only abutment-free, implantable, bone-anchored hearing system on the market, treating those with conductive hearing loss, mixed hearing loss and single-sided deafness. Fitted to the patient’s head with the use of small, implantable magnets, the Sophono Alpha System eliminates the problems associated with other bone conduction hearing systems. These include drilling a hole in the patient’s skull and installing a very noticeable screw that pokes out through the skin on the side of the head.

The article summarizing the study findings, with preliminary results on how Sophono’s closed-skin bone-anchored implant worked in children with ear atresia, appears in the February issue of Otology & Neurotology. The study, conducted in Hôpital d’Enfants Armand-Trousseau (Paris Childrens’ Hospital) in 2012, evaluated the results of children between 6 and 9 years old. All had high-grade ear atresia, defined as the absence an external ear canal and resulting in the child’s inability to hear in the affected ear. A review of patient benefit at six months of use with the Sophono system showed that the children experienced the following.

1.    Hearing levels improved from severe conductive loss to nearly normal hearing.

2.    A high level of overall satisfaction – among both children and their parents

3.    No pain or skin complications

4.    Statistical and clinical improvement in speech-in-noise, an indication of how well the children could understand speech in a noisy environment

Study authors were: Françoise Denoyelle, M.D., Ph.D.; Nicolas Leboulanger, M.D., Ph.D.; Cyrille Coudert; Olivia Mazzaschi, M.D.; Natalie Loundon, M.D.; Eric Vicaut; Natacha Tessier; and Eréa-Noël Garabedian, M.D.

“The results that the article presents confirm the hearing performance Sophono continually sees with those using the Sophono Alpha System – in terms of hearing ability, speech understanding and high levels of satisfaction,” says Jim Kasic, president and CEO of Sophono. “Children, in particular, benefit from Sophono’s abutment-free technology.”

Sophono, Inc. (http://www.sophono.com)
Sophono, Inc., is a medical device manufacturer specializing in implantable, bone conduction hearing devices. The company’s products are designed for individuals suffering from severe to profound hearing loss or impairment. The Sophono Alpha 2™ System is the only abutment-free, implantable, bone-anchored hearing system available today. Treating those with conductive hearing loss, mixed hearing loss, and single-ear deafness, the FDA-cleared Alpha 2 device eliminates the problematic abutment of devices by using magnets to affix external sound processors.

Sophono corporate headquarters and manufacturing operations reside in Boulder, Colo. The company maintains an office in Germany, works with more than 20 distributors, and is actively selling in more than 30 countries.

(end)

Read the full story at http://www.prweb.com/releases/2013/2/prweb10405031.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. EU Study Finds UK Health Product Benefit Metric Flawed
2. Notre Dame study explores the potential benefits and threats of nanotechnology research
3. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
4. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
5. Wysebridge Launches Patent Bar Exam Study Review
6. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
7. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
8. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
9. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
10. Study identifies targeted molecular therapy for untreatable NF1 tumors
11. Study Finds Proof of Acupuncture Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, was today awarded ... The awards program is based entirely on merit and decided upon by a ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market by ... (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published ... from USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
Breaking Biology News(10 mins):